无炎症性肠病的原发性硬化性胆管炎增加结直肠癌风险:一项多中心倾向评分匹配分析
基于TriNetX数据库的回顾性队列研究显示,无炎症性肠病(IBD)的原发性硬化性胆管炎(PSC)患者结直肠癌风险较无PSC/IBD人群升高(aHR=2.91;95%CI:1.6-6.0),合并IBD的PSC患者风险更高(aHR=6.5;95%CI:3.78-11.2)。PSC患者多种胃肠道恶性肿瘤风险亦升高(aHR=10.5;95%CI:7.3-15;p<0.0001)。
要点
- 无IBD的PSC患者结直肠癌风险较无PSC/IBD人群升高(aHR=2.91;95%CI:1.6-6.0)。
- PSC合并IBD患者结直肠癌风险更高(aHR=6.5;95%CI:3.78-11.2),UC亚组aHR=6.3(95%CI:3.2-12.4)。
- PSC患者多种胃肠道恶性肿瘤风险升高(aHR=10.5;95%CI:7.3-15;p<0.0001)。
核心结论
- PSC是无IBD情况下结直肠癌的独立危险因素,结果为真实世界证据。
- 作者认为需进一步研究以确定孤立性PSC患者能否从量身定制的结直肠癌监测策略中获益。
研究设计与样本
- 回顾性队列研究,使用TriNetX数据库纳入≥18岁PSC患者。
- 分为PSC合并IBD组与PSC无IBD组,并以1:1倾向评分匹配无PSC/IBD病史患者作为对照。
- 主要结局为首次诊断结直肠癌的风险,采用Kaplan-Meier分析和风险比(HR)及95%CI比较每日时间间隔的事件时间率。
主要发现
- 无IBD的PSC患者结直肠癌风险较无PSC/IBD队列升高(aHR=2.91;95%CI:1.6-6.0)。
- PSC合并IBD患者结直肠癌风险更高(aHR=6.5;95%CI:3.78-11.2),UC亚组aHR=6.3(95%CI:3.2-12.4)。
- PSC患者多种胃肠道恶性肿瘤风险升高(aHR=10.5;95%CI:7.3-15;p<0.0001),包括肝胆癌、胰腺癌和肝细胞癌。
关键数值与推荐
- 无IBD的PSC患者结直肠癌风险aHR=2.91(95%CI:1.6-6.0)。
- PSC合并IBD患者结直肠癌风险aHR=6.5(95%CI:3.78-11.2)。
- PSC合并UC患者结直肠癌风险aHR=6.3(95%CI:3.2-12.4)。
- PSC患者胃肠道恶性肿瘤风险aHR=10.5(95%CI:7.3-15;p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为需进一步研究以确定孤立性PSC患者能否从量身定制的结直肠癌监测策略中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC). However, the risk of CRC in patients with PSC without IBD remains uncertain. We aimed to evaluate the risk of CRC in patients with PSC without a history of IBD using a large national database. METHODS: We conducted a retrospective cohort study using the TriNetX database to identify patients ≥ 18 years with PSC. Patients were then divided into two groups, PSC with IBD (PSC-IBD cohort) and PSC without IBD (PSC non-IBD cohort), and were matched with patients without a history of PSC or IBD (non-PSC/non-IBD group) by using 1:1 propensity score matching. The primary outcome was the risk of first diagnosis of CRC. With censoring applied, Kaplan-Meier analysis with hazard ratios (HRs) and 95% CIs was used to compare time-to-event rates at daily time intervals. RESULTS: PSC patients without IBD were at increased risk of CRC compared to the non-PSC/IBD cohort (aHR = 2.91; 95% CI: 1.6-6.0). Patients with PSC and IBD exhibited a higher risk of CRC (aHR = 6.5; 95% CI: 3.78-11.2), especially among the UC cohort (aHR = 6.3; 95% CI: 3.2-12.4). Patients with PSC were at increased risk of various gastrointestinal malignancies (aHR = 10.5; 95% CI: 7.3-15; p < 0.0001), including hepatobiliary cancers, pancreatic cancer, and hepatocellular carcinoma. DISCUSSION: Our findings provide real-world evidence that PSC is an independent risk factor for colorectal cancer, even in the absence of concomitant IBD. These results support the need for further research to determine whether patients with isolated PSC may benefit from tailored CRC surveillance strategies.
引用
- Alsakarneh S, Aburumman R, Bilal M, et al. Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi-Centre Propensity Score Matched Analysis. Aliment Pharmacol Ther. 2025. PMID: 40704424. doi:10.1111/apt.70303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。